A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

ClinicalTrials.gov ID: NCT02393937

Public ClinicalTrials.gov record NCT02393937. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Metronidazole Gel 1%, to Metrogel® (Metronidazole Gel) 1% in the Treatment of Rosacea

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.

Study identification

NCT ID: NCT02393937
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: bioRASI, LLC; Industry
Enrollment: 963 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2015 (Type not available)
Primary completion: Jul 2015 (Actual)
Completion: Oct 2015 (Actual)
Last update posted: Sep 3, 2020

2015

United States locations

U.S. sites: 27
U.S. states: 13
U.S. cities: 26

Facility	City	State	ZIP	Site status
Not listed	Los Angeles	California	90036	—
Not listed	San Diego	California	92121	—
Not listed	Boca Raton	Florida	33486	—
Not listed	Clearwater	Florida	33761	—
Not listed	Miami	Florida	33126	—
Not listed	Miami	Florida	33136	—
Not listed	Miramar	Florida	33027q	—
Not listed	Ocala	Florida	34471	—
Not listed	Tampa	Florida	33634	—
Not listed	Lexington	Kentucky	40509	—
Not listed	Watertown	Massachusetts	02472	—
Not listed	Las Vegas	Nevada	89104	—
Not listed	New York	New York	10075	—
Not listed	High Point	North Carolina	27262	—
Not listed	Raleigh	North Carolina	27612	—
Not listed	Cincinnati	Ohio	45246	—
Not listed	Philadelphia	Pennsylvania	19103	—
Not listed	Warwick	Rhode Island	02886	—
Not listed	Mt. Pleasant	South Carolina	29464	—
Not listed	Austin	Texas	78759	—
Not listed	El Paso	Texas	79902	—
Not listed	Houston	Texas	77055	—
Not listed	Pflugerville	Texas	78660	—
Not listed	Plano	Texas	75093	—
Not listed	San Antonio	Texas	78229	—
Not listed	Arlington	Virginia	22203	—
Not listed	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02393937, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 3, 2020 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02393937 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →